NCT02969837 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02899052 Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02891811 Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy Status COMPLETED Phase PHASE2
NCT02867618 Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT02802163 Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Status WITHDRAWN Phase PHASE1/PHASE2
NCT02773030 A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02659293 Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02628704 Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma Status WITHDRAWN Phase PHASE2
NCT02597062 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02545907 A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Status COMPLETED Phase PHASE1/PHASE2
NCT02512926 Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Status COMPLETED Phase PHASE1
NCT02491359 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Status COMPLETED Phase PHASE2
NCT02474927 Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Status COMPLETED Phase PHASE2
NCT02415413 Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02412878 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Status COMPLETED Phase PHASE3
NCT02343042 Selinexor and Backbone Treatments of Multiple Myeloma Patients Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02341014 Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Status COMPLETED Phase PHASE1/PHASE2
NCT02335983 Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma Status COMPLETED Phase PHASE1